
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc is developing a range of cannabinoid-based formulations aimed at treating several conditions, notably Alzheimer's disease, with investigational drugs like IGC-AD1 demonstrating significant promise in preclinical studies. The company has raised its valuation based on a net present value (NPV) analysis, indicating substantial upside potential from the current share price. Additionally, anticipated positive data and progress in ongoing research are expected to act as catalysts for further stock performance.
Bears say
The financial outlook for IGC Pharma Inc remains negative primarily due to a consistent net loss of $1.6 million, equating to earnings per share of $(0.02), which aligns with recent consensus estimates but highlights ongoing financial challenges. Significant risks threaten the company's future, including balance sheet and liquidity concerns, potential failures of investigational drug candidates in clinical trials, and difficulties in obtaining necessary regulatory approvals. Additionally, broader macroeconomic factors, competitive pressures, and shifts in investor sentiment towards biotech stocks further complicate IGC Pharma's ability to achieve financial stability and growth.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares